Saturday 17 October 2026
Export RDY’s income statement to Excel — free account
Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.
13.05
0.15
+1.16%
Follow RDY
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 6 | 8 | 6 | 5 | 7 | 8 | 5 | 5 |
P/E ratio |
25.79 | 19.98 | 18.30 | 17.10 | 29.88 | 43.04 | 24.60 | 25.19 | 35.22 | 36.83 |
Altman Z-Score |
5.26 | 5.94 | 8.43 | 7.87 | 6.38 | 7.07 | 6.30 | 5.35 | 3.86 | 4.33 |
P/S ratio |
3.22 | 2.88 | 3.67 | 3.16 | 3.27 | 3.93 | 2.89 | 3.02 | 2.46 | 3.08 |
Altman Z″-Score (non-manufacturers) |
6.10 | 6.93 | 8.73 | 8.51 | 6.56 | 6.32 | 6.70 | 5.81 | 4.50 | 3.84 |
P/FCF ratio |
53.62 | 69.98 | 53.50 | 19.42 | 56.74 | 32.12 | 20.90 | 20.76 | 49.30 | 0.00 |
P/Operating CF |
77.38 | 42.42 | 89.82 | 39.07 | 80.42 | 66.55 | 477.74 | 67.96 | 63.22 | 47.79 |
Beneish M-Score |
(2.59) | (1.97) | (2.25) | (2.68) | (2.38) | (2.78) | (2.56) | (2.73) | (2.62) | (2.46) |
Dividend Safety Score |
74 | — | — | — | — | — | — | — | — | — |
P/B ratio |
2.84 | 2.78 | 3.66 | 3.36 | 3.68 | 4.30 | 3.25 | 3.32 | 2.76 | 3.50 |
Price to Tangible BV |
4.12 | 4.11 | 4.28 | 3.97 | 4.42 | 5.60 | 4.09 | 5.07 | 4.49 | 5.76 |
EV/Sales |
3.19 | 2.85 | 3.45 | 2.96 | 3.21 | 3.90 | 2.86 | 3.11 | 2.67 | 3.30 |
EV/EBITDA |
15.04 | 10.41 | 11.68 | 10.43 | 16.67 | 16.20 | 11.04 | 14.48 | 16.05 | 18.76 |
EV/Operating CF |
18.81 | 19.91 | 21.22 | 12.36 | 24.55 | 20.71 | 16.73 | 16.67 | 21.03 | 21.58 |
EV/FCF |
53.09 | 69.10 | 50.29 | 18.18 | 55.73 | 31.88 | 20.70 | 21.36 | 53.45 | (23.96) |
Quick Ratio |
1.13 | 1.14 | 1.69 | 1.58 | 1.20 | 1.03 | 1.06 | 1.09 | 0.89 | 0.66 |
Current Ratio |
1.80 | 1.92 | 2.58 | 2.41 | 1.93 | 1.78 | 1.79 | 1.92 | 1.57 | 1.18 |
Net Debt/EBITDA |
(0.15) | (0.13) | (0.75) | (0.71) | (0.30) | (0.12) | (0.10) | 0.40 | 1.25 | 1.24 |
Debt/Assets |
13.34% | 9.48% | 5.18% | 4.19% | 11.55% | 11.40% | 9.51% | 17.03% | 22.45% | 22.36% |
Debt/Equity |
0.20 | 0.14 | 0.07 | 0.06 | 0.18 | 0.18 | 0.14 | 0.27 | 0.40 | 0.40 |
Asset Turnover |
0.60 | 0.73 | 0.78 | 0.77 | 0.75 | 0.77 | 0.73 | 0.66 | 0.64 | 0.67 |
Operating CF/Net income |
1.33 | 0.82 | 0.82 | 1.31 | 1.19 | 2.07 | 1.53 | 1.53 | 1.83 | 1.78 |
Capex/Depreciation |
(1.78) | (1.94) | (1.77) | (1.49) | (1.33) | (0.98) | (0.46) | (0.52) | (0.93) | (3.63) |
Interest Coverage |
13.48 | 25.52 | 38.67 | 40.88 | 29.92 | 34.54 | 33.46 | 17.76 | 14.08 | 17.33 |
| 11.40% | 18.13% | 21.63% | 20.60% | 12.76% | 10.68% | 12.69% | 13.70% | 7.83% | 9.66% | |
| 7.63% | 12.72% | 15.60% | 14.09% | 8.30% | 7.03% | 8.17% | 8.09% | 4.41% | 5.70% | |
ROIC |
8.55% | 13.82% | 19.31% | 19.68% | 10.36% | 12.25% | 13.64% | 8.51% | 4.78% | 5.45% |
Return on Tangible Assets |
17.09% | 26.05% | 24.32% | 24.00% | 15.73% | 14.15% | 17.78% | 17.27% | 10.05% | 16.64% |
Average Days of Receivables |
110.01 | 101.33 | 104.92 | 107.60 | 113.66 | 95.54 | 105.12 | 94.49 | 104.43 | 98.69 |
Research and Development Expense of Revenue |
7.15% | 8.40% | 8.18% | 7.89% | 8.14% | 8.71% | 8.81% | 10.16% | 12.88% | 13.86% |
Selling, General and Administrative Expense of Revenue |
31.76% | 28.84% | 27.64% | 27.67% | 28.95% | 28.80% | 28.71% | 31.78% | 33.01% | 32.93% |
Intangible Assets out of Total Assets |
0.20 | 0.22 | 0.11 | 0.11 | 0.11 | 0.15 | 0.14 | 0.21 | 0.22 | 0.22 |
Share Based Compensation of Revenue |
0.08% | 0.13% | 0.15% | 0.17% | 0.28% | 0.31% | 0.30% | 0.27% | 0.32% | 0.28% |
Graham Net Nets |
0.10 | 0.10 | 0.14 | 0.15 | 0.11 | 0.07 | 0.11 | 0.06 | 0.03 | 0.01 |
Graham Number |
7.67 | 8.39 | 8.58 | 7.12 | 5.04 | 4.28 | 4.28 | 4.21 | 3.12 | 3.35 |
Earnings Yield |
3.88% | 5.00% | 5.46% | 5.85% | 3.35% | 2.32% | 4.06% | 3.97% | 2.84% | 2.71% |
Free Cash Flow Yield |
1.86% | 1.43% | 1.87% | 5.15% | 1.76% | 3.11% | 4.78% | 4.82% | 2.03% | (4.47%) |
Revenue per Share |
4.30 | 4.58 | 4.03 | 3.60 | 3.41 | 3.13 | 2.79 | 2.68 | 2.63 | 2.61 |
Operating CF per Share |
0.73 | 0.65 | 0.66 | 0.86 | 0.45 | 0.59 | 0.48 | 0.50 | 0.33 | 0.40 |
Capex per Share |
(0.47) | (0.47) | (0.38) | (0.28) | (0.25) | (0.21) | (0.09) | (0.11) | (0.20) | (0.76) |
Free Cash Flow per Share |
0.26 | 0.19 | 0.28 | 0.59 | 0.20 | 0.38 | 0.39 | 0.39 | 0.13 | (0.36) |
Cash per Share |
1.13 | 0.82 | 1.18 | 0.92 | 0.74 | 0.59 | 0.43 | 0.44 | 0.39 | 0.34 |
Shareholders Equity per Share |
4.87 | 4.74 | 4.05 | 3.38 | 3.03 | 2.85 | 2.48 | 2.44 | 2.34 | 2.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.87 | 4.74 | 4.05 | 3.38 | 3.03 | 2.85 | 2.48 | 2.44 | 2.34 | 2.30 |
Free Cash Flow |
215.00 | 157.00 | 230.00 | 487.00 | 163.00 | 317.00 | 320.00 | 324.00 | 109.00 | (299.00) |
Working Capital |
1,432.00 | 1,401.00 | 1,824.00 | 1,474.00 | 1,158.00 | 887.00 | 763.00 | 793.00 | 614.00 | 237.00 |
Capital Expenditures |
(392.00) | (388.00) | (315.00) | (229.00) | (207.00) | (171.00) | (76.00) | (91.00) | (168.00) | (631.00) |
Net Current Asset Value |
1,098.00 | 1,103.00 | 1,692.00 | 1,412.00 | 1,049.00 | 763.00 | 704.00 | 424.00 | 161.00 | 71.00 |
EV/EBIT |
21.18 | 12.88 | 14.24 | 12.74 | 23.35 | 22.51 | 15.23 | 22.91 | 31.84 | 34.45 |
Capex to Sales |
0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.03 | 0.04 | 0.08 | 0.29 |
Price to Operating Income |
21.39 | 13.05 | 15.15 | 13.61 | 23.77 | 22.68 | 15.38 | 22.28 | 29.36 | 32.17 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.18 | 0.17 | 0.19 | 0.19 | 0.19 | 0.22 | 0.24 | 0.23 | 0.20 | 0.20 |
Cash ROIC |
3.70% | 3.03% | 5.02% | 13.02% | 4.57% | 9.69% | 11.83% | 11.00% | 3.58% | (10.12%) |
Accounts Receivable Turnover |
3.35 | 3.77 | 3.63 | 3.40 | 3.63 | 3.85 | 3.73 | 3.71 | 3.60 | 3.59 |
Accounts Payable Turnover |
4.38 | 4.01 | 4.00 | 3.93 | 4.00 | 4.34 | 4.96 | 4.46 | 4.44 | 4.90 |
Inventory Turnover |
2.05 | 1.98 | 2.05 | 2.05 | 2.05 | 2.18 | 2.25 | 2.18 | 2.28 | 2.33 |
Average Days of Payables |
76.84 | 96.27 | 97.63 | 90.69 | 92.83 | 100.11 | 75.46 | 75.29 | 89.35 | 78.46 |
Days of Inventory on Hand |
176.13 | 192.08 | 200.79 | 166.73 | 184.84 | 191.28 | 158.77 | 174.25 | 161.70 | 166.77 |
Average Receivables |
1,068.50 | 1,010.50 | 922.50 | 881.00 | 779.50 | 673.00 | 621.50 | 600.00 | 605.50 | 605.00 |
Average Payables |
386.50 | 394.00 | 346.50 | 329.50 | 331.00 | 273.00 | 215.50 | 228.50 | 227.00 | 196.50 |
Average Inventory |
824.00 | 797.50 | 677.50 | 631.50 | 646.00 | 543.00 | 475.50 | 466.50 | 443.50 | 413.00 |
Average Assets |
5,973.50 | 5,211.00 | 4,283.00 | 3,888.00 | 3,745.00 | 3,355.50 | 3,170.00 | 3,362.00 | 3,427.50 | 3,262.00 |
Average Common Equity |
4,000.50 | 3,656.50 | 3,088.50 | 2,660.50 | 2,438.00 | 2,210.50 | 2,040.50 | 1,985.00 | 1,928.00 | 1,925.00 |
Columns are period end dates